View all IQVIA events
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
事業内容
-
医薬品・医療機器 臨床開発
-
Clinical Development in Japan
-
リアルワールド インサイト
-
市場データ
-
コンサルティング＆サービス
-
医療機関・保険者向け
-
テクノロジー
-
CSO事業
医薬品・医療機器 臨床開発
新時代の価値創造へ グローバルの総合力で革新的なパフォーマンスを IQVIAは、グローバルの先端知識と日本ローカルの深い知見を組み合わせた屈指の専門性に、データ・分析力・テクノロジーを掛け合わせた革新的なアプローチで、新時代における医薬品・医療機器開発の精度とスピードを加速し、製品価値の最大化を支援します。
概要医薬品・医療機器 臨床開発
Clinical Development in Japan
Our offerings provide access to all functions and services for partners to successfully navigate the regulatory processes and perform high quality clinical development in Japan.
概要リアルワールド インサイト
リアルワールド ソリューションに関する幅広いポートフォリオを通じて、製品ライフサイクルに臨床的および商業的側面の両方から価値をもたらすことをお約束します。
概要リアルワールド インサイト
コンサルティング＆サービス
世界最大規模のヘルスケア業界知識とチームを活かし、経営戦略から事業・組織の実装まで、End to Endでお客様の課題解決を支援いたします。
概要コンサルティング＆サービス
テクノロジー
IQVIAは、お客様の様々なニーズにお応えし続けるために ライフサイエンス業界に特化した革新的な ソリューションの充実に注力していきます。 当社のテクノロジーソリューションは、 コンプライアンスを遵守しながらも、 医療全体の高度化と業績拡大を目指すお客様を、 強力にご支援してまいります。
概要テクノロジー ソリューション
Summary
Japan is—and will remain—the second largest market for branded pharmaceuticals and innovation. Continued investment in development and commercialization of pharmaceuticals in Japan is creating many opportunities and growing the potential for multinational biopharma companies. This is driven in part by ongoing regulatory and government initiatives that reward innovation, shifts in population demographics, and increased disease awareness and identifiable patient populations, amongst other factors. Join IQVIA Japan as we discuss how to seize these opportunities and the strong potential outlook for the market in the coming years
Key Takeaways
- To obtain the information about the market in Japan
- How to seize the opportunity in this strong potential market
- The potential of the market in Japan in coming year
Speaker
Alan Thomas
Director, Thought Leadership IQVIA Solutions Japan K.K.
Alan Thomas joined IQVIA (then IMS Japan) in 1999, supporting multinational pharma companies in the Japan market. In 2002, he was appointed Manager Japan Global Accounts, supporting Japanese pharma companies with sales, marketing and consulting services for Japan, Europe, USA, China and AsiaPacific. In 2004, he was appointed Global Key Account Manager and in 2006 he was appointed Global Key Account Director, a position he held until January 2011 when he was appointed Director Global Pharma Segmentation and Account Management, a role in which Alan worked with IMS teams globally to deliver expanded business intelligence and decision support to pharma companies - both Japanese and foreign multinationals. In 2012, Alan took on an expanded role supporting the wider healthcare stakeholder community. In this role, Alan supported the IQVIA thought leadership and market insights initiatives globally, and strengthened Japan’s thought leadership position. In 2016, Alan was appointed Director Thought Leadership and in this role he continues to engage with the wider healthcare stakeholder community, supporting the integrated IQVIA thought-leadership and market insights teams, and leading Japan’s thought leadership position.